share_log

Phio Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Phio Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Phio Pharmaceuticals | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/15 04:51

Moomoo AI 已提取核心信息

Phio Pharmaceuticals reported Q2 2024 financial results with a net loss of $1.85 million ($3.62 per share), compared to a $2.55 million loss in Q2 2023. Cash and equivalents stood at $4.7 million as of June 30, 2024, down from $8.49 million at year-end 2023. The company completed a $2.6 million financing in July 2024 through warrant exercises.Research and development expenses decreased 37% to $866,000, driven by cost rationalization measures and reduced clinical consulting fees. General and administrative expenses declined 10% to $1.05 million due to lower salary and professional fee expenses. The company terminated its clinical collaboration agreement with AgonOx in May 2024.Phio's lead candidate PH-762 is advancing in a Phase 1b trial for skin cancers, with the first dose cohort completed and dose escalation recommended. The company expects current cash resources to fund operations into Q2 2025 but noted substantial doubt about its ability to continue as a going concern without additional funding.
Phio Pharmaceuticals reported Q2 2024 financial results with a net loss of $1.85 million ($3.62 per share), compared to a $2.55 million loss in Q2 2023. Cash and equivalents stood at $4.7 million as of June 30, 2024, down from $8.49 million at year-end 2023. The company completed a $2.6 million financing in July 2024 through warrant exercises.Research and development expenses decreased 37% to $866,000, driven by cost rationalization measures and reduced clinical consulting fees. General and administrative expenses declined 10% to $1.05 million due to lower salary and professional fee expenses. The company terminated its clinical collaboration agreement with AgonOx in May 2024.Phio's lead candidate PH-762 is advancing in a Phase 1b trial for skin cancers, with the first dose cohort completed and dose escalation recommended. The company expects current cash resources to fund operations into Q2 2025 but noted substantial doubt about its ability to continue as a going concern without additional funding.
Phio Pharmaceuticals公布2024年第二季度财务结果，净亏损为185万美元（每股3.62美元），相比2023年第二季度的255万美元亏损有所减少。截至2024年6月30日，公司现金及等价物为470万美元，较2023年年末的849万美元有所下降。公司于2024年7月通过认股权证行使完成了260万美元的融资。研发费用减少37%，至866,000美元，主要受成本合理化措施和临床咨询费用减少的推动。一般及管理费用下降10%，至105万美元，原因是薪资和专业费用支出降低。公司于2024年5月终止了与AgonOx的临床合作协议。Phio的主导候选药物PH-762在皮肤癌的10亿期试验中取得进展，首次剂量组已完成，并推荐进行剂量递增。公司预计当前现金资源将支持运营直到2025年第二季度，但指出在没有额外融资的情况下继续作为持续经营实体的能力存在重大疑虑。
Phio Pharmaceuticals公布2024年第二季度财务结果，净亏损为185万美元（每股3.62美元），相比2023年第二季度的255万美元亏损有所减少。截至2024年6月30日，公司现金及等价物为470万美元，较2023年年末的849万美元有所下降。公司于2024年7月通过认股权证行使完成了260万美元的融资。研发费用减少37%，至866,000美元，主要受成本合理化措施和临床咨询费用减少的推动。一般及管理费用下降10%，至105万美元，原因是薪资和专业费用支出降低。公司于2024年5月终止了与AgonOx的临床合作协议。Phio的主导候选药物PH-762在皮肤癌的10亿期试验中取得进展，首次剂量组已完成，并推荐进行剂量递增。公司预计当前现金资源将支持运营直到2025年第二季度，但指出在没有额外融资的情况下继续作为持续经营实体的能力存在重大疑虑。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。